HER2+ Non-Small Cell Lung Cancer Market Growing Rapidly, Estimates DelveInsight | Fate Therapeutics, Eli Lilly and Company, Pharmacyclics LLC, MacroGenics, Taiho Oncology, Inc., Jiangsu HengRui Medicine are Expected to Contribute to Growth

The dynamics of the HER2+ non-small cell lung cancer market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world and increasing incidence during the forecast period of 2023-2032

LAS VEGAS, April 18, 2023 /PRNewswire/ -- DelveInsight's HER2+ Non-Small Cell Lung Cancer Market Insights report includes a comprehensive understanding of current treatment practices, HER2+ non-small cell lung cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the HER2+ Non-Small Cell Lung Cancer Market Report

• As per DelveInsight analysis, the HER2+ non-small cell lung cancer market is expected to grow positively at a significant CAGR during the study period (2019–2032).
• According to Auliac et al. (2019), in France, in non-small cell lung cancers (NSCLCs), HER2 mutation is a rare event, occurring in approximately 1% of the overall lung cancer population. This rate increases to 4.8% in EGFR wild-type lung adenocarcinoma resection specimens.
• Leading HER2+ non-small cell lung cancer companies such as Fate Therapeutics, Eli Lilly and Company, Pharmacyclics LLC, MacroGenics, Taiho Oncology, Inc., Jiangsu HengRui Medicine, Hanmi Pharmaceutical, Spectrum Pharmaceuticals, AstraZeneca, Daiichi Sankyo, Dizal Pharmaceuticals, Takeda Pharmaceuticals, and others are developing novel HER2+ non-small cell lung cancer drugs that can be available in the HER2+ non-small cell lung cancer market in the coming years.
• Some key therapies for HER2+ non-small cell lung cancer treatment include FATE-NK100, Abemaciclib, FT538, FT536, Ibrutinib + Durvalumab, MGD013, TAS-116, Pyrotinib, Poziotinib, Trastuzumab deruxtecan, DZD9008, Mobocertinib (TAK-788), and others.
• The emerging HER2+ non-small cell lung cancer therapies are in their clinical trials' mid and late phases and are awaiting a launch to make the pipeline robust.

Discover which therapies are expected to grab the major HER2+ non-small cell lung cancer market share @ HER2+ Non-Small Cell Lung Cancer Market Report

HER2+ Non-Small Cell Lung Cancer Overview

NSCLC is the most common type of lung cancer, accounting for over 85% of all cases. Adenocarcinomas, squamous, big cell carcinomas, and numerous other forms that occur less commonly, including adenosquamous and sarcomatoid carcinomas, are the most common subtypes of NSCLC. Several adenocarcinoma genes are altered (by mutations, amplification, or rearrangements): EGFR, EML4-ALK, KRAS, ROS1, RET, BRAF, TP53, and FGFR1, PIK3CA, DDR2, MET, SOX2, PTEN, CDKN2A.

HER2 changes in NSCLC include gene mutations and amplifications. HER2 mutations and amplifications have been found in 2-3% and 2-5% of lung adenocarcinomas, respectively. HER2 is shown to be increased in 12-13% of NSCLC cases that have developed resistance to EGFR-TKIs. Immunohistochemistry (IHC) for protein overexpression, fluorescent in situ hybridization (FISH) for gene amplification, and next-generation sequencing (NGS) for gene alterations are all laboratory methods used to test HER2-positive in NSCLC.

HER2+ Non-Small Cell Lung Cancer Epidemiology Segmentation

As per the study conducted by Ninomiya et al. (2019), in Japan, out of 1,126 tumors screened tumors, 34 (3.0%) were IHC3þ, and 34 (3.0%) were IHC2þ/ FISHþ. Among the 724 epidermal growth factor receptor wild-type tumors, 21 (2.9%) were HER2-mutant tumors, including A775-G776insYVMA (n=15). Female patients had HER2-mutant tumors more frequently, whereas both IHC3þ and IHC2þ/FISHþ tumors were detected more often in male subjects and smokers. Patients with a HER2-aberrant tumor had a significantly worse prognosis than those with epidermal growth factor receptor-positive and anaplastic lymphoma kinase-positive tumors, possibly due to the low proportion that received HER2-targeted therapies (n=15 [26%]) and low response rates of 0% and 14% in patients with HER2-overexpressing and HER2-mutant tumors, respectively.

The HER2+ non-small cell lung cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Incident Cases of Non-Small Cell Lung Cancer
• Total Incident Cases of Non-Small Cell Lung Cancer Patients by Histology
• Total Diagnosed Cases of Non-Small Cell Lung Cancer patients by Stages
• Total Non-Small Cell Lung Cancer Cases of Patients by HER2-positive Mutation
• Total Treated Cases of Non-Small Cell Lung Cancer Patients by Line of Therapies 

Download the report to understand which factors are driving HER2+ non-small cell lung cancer epidemiology trends @ HER2+ Non-Small Cell Lung Cancer Epidemiological Insights

HER2+ Non-Small Cell Lung Cancer Treatment Market 

There are currently no approved drugs for HER2-mutant lung malignancies, while treatment responses to both chemotherapies and HER2-targeted therapies have been recorded. Developing highly effective and tolerated HER2-targeted therapies is critical for this population. HER2 is important in cellular development and replication, and its overexpression has been linked to the uncontrolled growth of cancer. Given the clinical experience of targeting HER2 mutations in breast cancer, similar therapeutic options are being investigated for HER2-mutated lung cancer. Pemetrexed-based chemotherapy is still an important part of treatment for patients with HER2-mutant NSCLC. Pemetrexed belongs to a class of drugs known as antifolate antineoplastic agents. It works by preventing the function of a chemical in the body that may aid in the proliferation of cancer cells. 

When provided as an initial therapy, HER2-TKI may provide better therapeutic advantages than when given as a second-line therapy. Refining the patient population based on HER2 variation patterns may aid in the success of anti-HER2 treatment in lung cancer.HER2 mutations are rapidly emerging as a promising pharmacological target, although the optimal choice of HER2-targeted medicines is unknown. For HER2-mutant advanced lung cancer patients, standard chemotherapy appears to be administered first.

The National Comprehensive Cancer Network (NCCN) recommends trastuzumab or afatinib as viable therapies for patients with HER2 mutations in non-small cell lung cancer. Several phase I/II trials are now underway to evaluate the efficacy of various irreversible pan-HER receptor family inhibitors. Currently, the HER2 mutation is emerging as a promising druggable target; however, the optimal choice of targeted therapy is unknown.

To know more about HER2+ non-small cell lung cancer treatment, visit @ HER2+ Non-Small Cell Lung Cancer Treatment Drugs 

Key HER2+ Non-Small Cell Lung Cancer Therapies and Companies

• FATE-NK100: Fate Therapeutics
• Abemaciclib: Eli Lilly and Company
• FT538: Fate Therapeutics
• FT536: Fate Therapeutics
• Ibrutinib + Durvalumab: Pharmacyclics LLC
• MGD013: MacroGenics
• TAS-116: Taiho Oncology, Inc.
• Pyrotinib: Jiangsu HengRui Medicine
• Poziotinib: Hanmi Pharmaceutical/Spectrum Pharmaceuticals
• Trastuzumab deruxtecan: AstraZeneca/Daiichi Sankyo
• DZD9008: Dizal Pharmaceuticals
• Mobocertinib (TAK-788): Takeda Pharmaceuticals

Learn more about the FDA-approved drugs for HER2+ non-small cell lung cancer @ Drugs for HER2+ Non-Small Cell Lung Cancer Treatment 

HER2+ Non-Small Cell Lung Cancer Market Dynamics

The dynamics of the HER2+ non-small cell lung cancer market are expected to change in the next years due to developments in diagnosis methodologies, increased disease awareness, increased healthcare spending globally, and breakthroughs in research and development. In addition, several leading pharma companies are working diligently to develop therapies for HER2+ non-small cell lung cancer treatment. Moreover, the pipeline for HER2+ non-small cell lung cancer is quite robust; many prospective therapies are being researched for HER2+ non-small cell lung cancer treatment, and it is safe to expect that the HER2+ non-small cell lung cancer treatment space will have a substantial impact on the HER2+ non-small cell lung cancer market throughout the forecast period. The predicted launch of novel therapies with improved efficacy is expected to drive the growth of the HER2+ non-small cell lung cancer market in the 7MM.

However, several factors are impeding the growth of the HER2+ non-small cell lung cancer market. Moreover, the HER2+ non-small cell lung cancer market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the HER2+ non-small cell lung cancer market growth.

Scope of the HER2+ Non-Small Cell Lung Cancer Market Report

• Therapeutic Assessment: HER2+ Non-Small Cell Lung Cancer current marketed and emerging therapies
• HER2+ Non-Small Cell Lung Cancer Market Dynamics: Attribute Analysis of Emerging HER2+ Non-Small Cell Lung Cancer Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, HER2+ Non-Small Cell Lung Cancer Market Access and Reimbursement

Discover more about HER2+ non-small cell lung cancer drugs in development @ HER2+ Non-Small Cell Lung Cancer Clinical Trials

Table of Contents

Related Reports

HER2+ Non-Small Cell Lung Cancer Epidemiology Forecast

HER2+ Non-Small Cell Lung Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted HER2+ non-small cell lung cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

HER2-mutant Non-Small Cell Lung Cancer Pipeline

HER2-mutant Non-Small Cell Lung Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HER2-mutant non-small cell lung cancer companies, including Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, among others.

Non-Small Cell Lung Cancer Market

Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-small cell lung cancer companies, including Novartis Pharmaceuticals, AbbVie, Janssen Pharmaceuticals, Xcovery, Eli Lilly and Company, Sanofi, Pfizer, among others.

Small-cell Lung Cancer Pipeline

Small-cell Lung Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key small cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, among others.

Small Cell Lung Cancer Market

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced small cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, among others.

Other Trending Reports

Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market 

Related Healthcare Blogs

Upcoming Oncological Drugs in 2023

Metastatic Castration-Sensitive Prostate Cancer Treatment Market

Checkpoint Inhibitor Refractory Cancer Market

Promising Oncolytic Virues Candidates in Pipeline

ENHERTU's Journey in Cancer Treatment and Management

Potential of PD-1 and PD-L1 Inhibitors in Cancer Management

Evolving EGFR NSCLC Treatment Market Dynamics

Emerging Role of Digital Health in the Field of Oncology

Related Cases Studies

Competitive Intelligence

Market Assessment

Product Assessment

Epidemiology Assessment

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg